



1646

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Snyder *et al.*

Serial No.: 10/023,603

Group Art Unit: 1646

Filed: December 17, 2001

Examiner: Not Yet Assigned

For: Nonpeptide Agonists and Antagonists of Vasopressin Receptors

Assistant Commissioner for Patents
Washington, DC 20231

March 28, 2002

RECEIVED
APR 05 2002
TECH CENTER 1600/2900


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publication listed on the accompanying Form PTO-1449A. A copy of the listed reference is enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

If the Examiner determines a fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to Deposit Account No. 11-0980.

Respectfully submitted,


Josephine Young
Registration No. 48,308


KING & SPALDING
191 Peachtree Street
Atlanta, GA 30303
404-572-4600 (Telephone)
404-572-5145 (Facsimile)



CERTIFICATE OF MAILING (37 CFR 1.8a)

RECEIVED
APR 05 2002
TECH CENTER 1600/2900

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.


Aisha Whitted

Date: March 28, 2002

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/023,603
Filing Date	December 17, 2001
First Named Inventor	Snyder <i>et al.</i>
Group Art Unit	1646
Examiner Name	N/A
Attorney Docket Number	18085.105229 (EMU2090US)

Sheet 2 of 2

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	BA	CALTABIANO, S., <i>et al.</i> "[d(CH ₂) ₅ Tyr(Me)]AVP." <i>Drugs of the Future</i> . 13(1):25-30, 1988.	
	BB	LASZLO, F. A., <i>et al.</i> "Pharmacology and Clinical Perspectives of Vasopressin Antagonists." <i>Pharmacol. Rev.</i> 43(1):73-108, 1991.	
	BC	LASZLO, F. A., <i>et al.</i> "Clinical Perspectives for Vasopressin Antagonists." <i>Drug News Perspect.</i> 6(8):591-599, 1993.	
	BD	MIURA, Y., <i>et al.</i> "The effect of OPC-21268, an oral, nonpeptide arginine vasopressin V1 receptor antagonist, on a patient with congestive heart failure." <i>Clin. Nephrol.</i> 40(1):60-61, 1993.	
	BE	NORTH, W.G. "Neuropeptide Production by Small Cell Carcinoma: Vasopressin and Oxytocin as Plasma Markers of Disease." <i>J. Clin. Endocrinol.</i> 73(6):1316-1320, 1991.	
	BF	SEARLES, R.V., <i>et al.</i> "Effect of Intracameral (IC) Vasopressin (AVP) Infusion on Intraocular Pressure (IOP) During Head Down Tilt (HDT)." <i>Faseb J.</i> 8(5):A587(3398), March 18, 1994.	
	BG	STUMP, D.L. <i>et al.</i> "The Use of Vasopressin in the Treatment of Upper Gastrointestinal Haemorrhage." <i>Drugs</i> . 39(1):38-53, 1990.	
	BH	YAMAMURA, Y., <i>et al.</i> "Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V ₂ receptor antagonist." <i>Br. J. Pharmacol.</i> 105:787-791, 1992.	
	BI	YAMAMURA, Y., <i>et al.</i> "OPC-21268, An Orally Effective, Nonpeptide Vasopressin V1 Receptor Antagonist." <i>Science</i> . 252:572-574, April 26, 1991.	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/023,603
Filing Date	December 17, 1991
First Named Inventor	Snyder <i>et al.</i>
Group Art Unit	1646
Examiner Name	N/A
Attorney Docket Number	18085.105229 (EMU2090US)

RECEIVED
APR 8 5 2002
TECH CENTER 1600/2900

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	5,258,510		Ogawa <i>et al.</i>	11-02-1993	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				
	AB	WO	91/05549		Ogawa <i>et al.</i>	02-05-1991		
	AC	WO	94/04525		Ogawa <i>et al.</i>	03-03-1994		
	AD	WO	94/12476		Kikuchi <i>et al.</i>	09-06-1994		
	AE	WO	94/14796		Matsumoto <i>et al.</i>	07-07-1994		
	AF	WO	94/20473		Matsuhisa <i>et al.</i>	15-09-1994		
	AG	EP	0 470 514		Ogawa <i>et al.</i>	12-02-1992		
	AH	EP	0 514 667		Ogawa <i>et al.</i>	25-11-1992		
	AI	EP	0 533 240		Erb <i>et al.</i>	24-03-1993		
	AJ	EP	0 533 242		Bock <i>et al.</i>	24-03-1993		
	AK	EP	0 533 243		Gilbert <i>et al.</i>	24-03-1993		
	AL	EP	0 533 244		Bock <i>et al.</i>	24-03-1993		
	AM	EP	0 620 216		Setoi <i>et al.</i>	19-10-1994		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	AN	ANDERSSON, K.E. <i>et al.</i> "Desomino-8-D-Arginine Vasopressin (DDAVP): Pharmacology and Clinical Use." <i>Drugs of Today</i> . 24(7):509-528, 1988.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.